Branded

PHILADELPHIA — An investigational insulin being developed by Novo Nordisk significantly reduced the rate of hypoglycemia at night in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented at the 72nd Scientific Sessions of the American Diabetes Association.

BENTONVILLE, Ark. — Walmart has partnered with En-Vision America to launch a pilot program that provides those who cannot read standard print a safe and easy way to access the information on their prescriptions.

SCOTTSBORO, Ala. — Government authorities are working to educate independent pharmacy owners on prescription drug abuse, an independent pharmacy network said.

In an event sponsored by American Associated Pharmacies in San Diego, Drug Enforcement Administration deputy assistant administrator for the Office of Diversion Control Joseph Rannazzisi discussed topics related to prescription drug abuse. Rannazzisi explained how drug abusers divert prescription drugs through doctor shopping, forged prescriptions, theft and the Internet.

NEW YORK — The Food and Drug Administration has approved a drug made by GlaxoSmithKline and XenoPort for treating pain associated with shingles.

The drug makers announced Thursday the approval of Horizant (gabapentin enacarbil) extended-release tablets for managing post-herpetic neuralgia. The drug already had FDA approval for treating restless legs syndrome. The approval entitles XenoPort to a $10 million milestone payment from GSK, according to a collaborative agreement between the two companies.

HYDERABAD, India — A generic drug maker in India and a German pharmaceutical company will collaborate to develop biosimilars.

Dr. Reddy's Labs and Merck KGaA subsidiary Merck Serono announced a partnership to develop biosimilar cancer treatments, most of them monoclonal antibodies, for global markets. Based in Darmstadt, Germany, Merck KGaA operates in the United States under the name EMD to distinguish itself from U.S. drug maker Merck.

HOUSTON — Novo Nordisk is starting an organization in Houston designed to provide assistance to local diabetes education programs, the Danish drug maker said Tuesday.

The company announced that it was accepting applications from local organizations for funding from Novo Nordisk Community Care Houston, one of more than 20 Novo Nordisk Community Care programs started in 2011 that provide funding to local groups. The drug maker is investing $80,000 on the Houston initiative.

BALTIMORE — The Food and Drug Administration has approved a new dosage of an antibiotic drug made by Lupin Pharmaceuticals, Lupin said Tuesday.

The Mumbai, India-based drug maker announced the approval of Suprax (cefixime) capsules in the 400-mg strength and plans to start shipping the drug "in the near future." The new approval adds to existing suspensions containing 100 mg per 5 mL and 200 mg per 5 mL.

The drug is used to treat infections such as pneumonia, gonorrhea and others.

DEERFIELD, Ill. — Drug maker Takeda Pharmaceutical has finished its purchase of URL Pharma, the companies said Monday.

Japan-based Takeda announced in April that it would buy URL for $800 million. The acquisition, through local subsidiary Takeda Pharmaceuticals USA, gives Takeda control of the gout drug Colcrys (colchicine). URL will report to Takeda Pharmaceuticals USA president Douglas Cole, and the acquisition is expected to boost 2012 sales by $550 million, Takeda said.